Back to results
US 2026/0308228 A1Published application
Mhc class i molecules
AssigneeImmudex ApS
InventorsThomas Holberg BLICHER, Tobias Guldbech MORTENSEN, Liselotte BRIX
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to MHC class I molecules, such as HLA-E, and peptide-MHC class I complexes with improved stability and/or refolding yield due to one or more introduced disulphide bridges. The disclosure further provides MHC class I multimers, cells, such as stem cells, comprising said MHC class I molecules, and various methods for their use.
Claims21
-90. (canceled)
An MHC class I molecule comprising or consisting of at least amino acids 1-276 of the amino acid sequence as set forth in SEQ ID NO:
- 1 or 2, or a variant of said MHC class I molecule having at least 90% sequence homology or identity thereto, such as at least 95% sequence homology or identity thereto, or such as at least 98% sequence homology or identity thereto,
- with the proviso that the amino acids corresponding to positions
- i) 4 and 102 of SEQ ID NO:
- 1 or 2, or
- ii) 12 and 94 of SEQ ID NO:
- 1 or 2, or
- iii) 23 and 37 of SEQ ID NO:
- 1 or 2, or
- iv) 115 and 125 of SEQ ID NO:
- 1 or 2
- have been mutated to cysteines and linked by a disulfide bridge, and wherein the MHC class I molecule has increased stability compared to a corresponding wild type MHC class I molecule of identical sequence except not comprising said cysteine mutations linked by a disulfide bridge.
8 more elements
Dependencies are inferred from the claim text.